<DOC>
	<DOCNO>NCT00717067</DOCNO>
	<brief_summary>The purpose study ass whether dose adjustment need patient renal impairment .</brief_summary>
	<brief_title>Pharmacokinetics , Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Stable Renal Function define ≤20 % ( 25 % normal renal function ) difference 2 measurement serum creatinine obtain 2 occasion separate least 2 week . Body Mass Index ( BMI ) approximately 18 40 kg/m2 inclusive . Total body weight &gt; 50 kg ( 110 lb ) . Male female subject age 18 85 year . Subjects acute renal disease and/or history renal transplant . Supine BP Screening ≥160 mm Hg systolic ≥95 mm Hg diastolic . Supine BP Screening ≤80 mm Hg systolic ≤40 mm Hg diastolic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>maraviroc , pharmacokinetics , renal impairment</keyword>
</DOC>